MyLeukemiaTeam

For Chronic Lymphocytic Leukemia (CLL) with a chromosome 17 mutation and deletion of TP53, ibrutinib is the preferred first-line treatment if a clinical trial is unavailable. If a second round of treatment is needed, options include:

- Ibrutinib
- Venetoclax with rituximab
- Idelalisib
- Duvelisib

These treatments are Show Full Answer

For Chronic Lymphocytic Leukemia (CLL) with a chromosome 17 mutation and deletion of TP53, ibrutinib is the preferred first-line treatment if a clinical trial is unavailable. If a second round of treatment is needed, options include:

- Ibrutinib
- Venetoclax with rituximab
- Idelalisib
- Duvelisib

These treatments are recommended due to their effectiveness in managing CLL with these specific genetic markers.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Chronic Lymphocytic Leukemia Treatment Options | MyLeukemiaTeam

What Is CLL? Prevalence, Prognosis, Treatment, and More | MyLeukemiaTeam